替罗非班治疗中危急性冠脉综合征的评价
Effect and safety evaluation of tirofiban on medial dangerous acute coronary syndrome
李岚 1姜述斌 1帕尔哈提 1张保俭 1毛拉提 1马俊 1许力舒1
作者信息
- 1. 新疆医科大学第四附属医院心脏中心,新疆,乌鲁木齐,830000
- 折叠
摘要
目的:探讨阿司匹林、氯吡格雷、低分子肝素、盐酸替罗非班(四联)联合使用治疗中危非ST段升高急性冠脉综合征患者临床治疗效果和安全性.方法:选择住院中危非ST段升高急性冠脉综合征患者117例,其中观察组57例,对照组60例,所有患者均服用阿司匹林、氯吡格雷,皮下注射低分子肝素,在此基础上观察组患者给予静脉输注盐酸替罗非班2～3 d.结果:观察组比对照组在7 d内全因死亡、顽固性心绞痛发生率、4 d内急诊经皮冠状动脉介入治疗(PCI)率方面均有下降(P＜0.05),但再次心肌梗死的发生率方面无统计学差异.观察组内轻度出血发生率高于对照组(P＜0.05).结论:四联治疗中危非ST段升高急性冠脉综合征患者是有效和安全的.
Abstract
AIM: To explore the efficacy and safety of quadruple therapy of aspirin, clopidogrel, low molecular weight heparin (LMWH) and tirofiban hydrochloride in the treatment of patients with medial dangerous non-ST-segment elevation acute coronary syndrome(NSTE-ACS). METHODS: Totally, 117 hospitalized patients with medial dangerous NSTE-ACS were included in the study, 57 of whom were assigned to observation group and 60 of whom to control group. In addition to aspirin, elopidogrel and hypodermically injected LMWH given to all the patients in both groups, tirofiban was given intravenously in observation group. RESULTS: Significant decrease in all-cause death, occurrence of refractory angina pectoris and within-d-day emergency PCI was observed in observation group compared with that in control group (P＜0.05), but no marked difference was found in the recurfence of myocardial infarction. More mild hemorrhage occurred in observation group compared with that in control group (P＜ 0.05). CONCLUSION: Quadruple therapy is safe and effective in the treatment of medial dangerous non-ST-segment elevation ACS.
关键词
替罗非班/急性冠脉综合征/治疗Key words
firofiban/acute coronary syndrone引用本文复制引用
出版年
2009
NETL
NSTL
维普
万方数据